Investigational drug · Phase 2
Tacrolimus prolonged release
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Intestine Transplantation, Kidney Transplantation, Lung Transplantation.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
26
Any phase or sponsor naming "Tacrolimus prolonged release"
First trial start
2011
May 25, 2011
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tacrolimus prolonged release", any sponsor or status.
Conditions studied
As listed on its trial records.
- Intestine Transplantation
- Kidney Transplantation
- Lung Transplantation
- Liver Transplantation
- Heart Transplantation
Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Tacrolimus prolonged release" as an intervention, largest first.
- A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.Pivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01363752 · 853 participants · Start Mar 8, 2011 · Primary completion Sep 18, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Kidney Transplantation
Sites: New Lambton, Australia; Perth, Australia; Innsbruck, Austria · 58 sites in all
- Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a TransplantPivotal-lookingCompleted
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT02118896 · 850 participants · Start Feb 24, 2003 · Primary completion Oct 7, 2009
Drug: FK506E · For: Heart Transplantation; Liver Transplantation; Kidney Transplantation
Sites: Cincinnati, Ohio; Camperdown, Australia; Brisbane, Australia · 105 sites in all
Chiesi Farmaceutici S.p.A.Industry
NCT02432833 · 428 participants · Start May 2015 · Primary completion Jan 24, 2017
Drug: ENVARSUS®; PROGRAF® and 1 more · For: End Stage Renal Disease
Sites: Parma, Italy
Beijing Tsinghua Chang Gung HospitalAcademic, hospital or other
NCT06147648 · 352 participants (planned) · Start Dec 1, 2023 · Primary completion Jul 30, 2025
Drug: Tacrolimus Sustained-release Capsules · For: Liver Transplantation
- Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release DrugsPivotal-lookingActive, not recruiting
Edward GeisslerAcademic, hospital or other
NCT06268769 · 322 participants · Start Mar 9, 2024 · Primary completion Feb 4, 2026
Drug: Tacrolimus Pill; Tacrolimus capsule · For: Immunosuppression
Sites: Aachen, Germany; Berlin, Germany; Bochum, Germany · 13 sites in all
- Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant RecipientsPivotal-lookingCompleted
Astellas Pharma China, Inc.Astellas (ALPMY)
NCT03644485 · 284 participants · Start Oct 21, 2018 · Primary completion Jul 15, 2022
Drug: Tacrolimus immediate-release formulation; Tacrolimus prolonged-release formulation and 3 more · For: Kidney Transplant
Sites: Beijing, China; Changsha, China; Guangzhou, China · 14 sites in all
- Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal AllograftsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00933231 · 281 participants · Start Aug 17, 2009 · Primary completion May 11, 2015
Drug: tacrolimus; tacrolimus and 5 more · For: Kidney Transplantation
Sites: Calgary, Canada; Edmonton, Canada; Winnipeg, Canada · 13 sites in all
- Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant RecipientsPivotal-lookingCompleted
Edward GeisslerAcademic, hospital or other
NCT04720326 · 268 participants · Start Dec 23, 2020 · Primary completion Jan 25, 2024
Drug: Tacrolimus Pill; Tacrolimus capsule · For: Prophylaxis Against Liver Transplant Rejection
Sites: Aachen, Germany; Berlin, Germany; Essen, Germany · 15 sites in all
- Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control TrialPivotal-lookingStatus unknown
Medical University of WarsawAcademic, hospital or other
NCT03603548 · 200 participants (planned) · Start Jul 9, 2018 · Primary completion Jul 9, 2023
Drug: Envarsus; Advagraf · For: Liver Transplant Rejection; Immunosuppression
Sites: Warsaw, Poland
- A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver TransplantPivotal-lookingStatus unknown
Chang Gung Memorial HospitalAcademic, hospital or other
NCT03216447 · 150 participants (planned) · Start Nov 23, 2017 · Primary completion Aug 31, 2023
Drug: Advagraf; Prograf · For: Liver Transplantation
Sites: Taoyuan, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Tacrolimus Trough Intravariability in Patients Treated With the Prolonged-Release Formulation Is a Risk Factor for Acute Graft Rejection.
Mira FS, Figueiredo C, Rodrigues L, et al. · Exp Clin Transplant 2021
- A simple and easy-to-perform liquid chromatography-mass spectrometry method for the quantification of tacrolimus and its metabolites in human whole blood. Application to the determination of metabolic ratios in kidney transplant patients.
Chavant A, Jourdil JF, Jouve T, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2021
- Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome.
Han Y, Du SQ, Xiao HJ, et al. · Beijing Da Xue Xue Bao Yi Xue Ban 2017
- Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation.
Snowsill TM, Moore J, Mujica Mota RE, et al. · Nephrol Dial Transplant 2017
- Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients.
Krejci K, Zadrazil J, Lackova E, et al. · Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016
- Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients.
Tanzi MG, Undre N, Keirns J, et al. · Clin Transplant 2016
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.